Anti-Aging Therapeutics Volume XIV

A4M American Academy

Description

Proceedings of the American Academy of Anti-Aging Medicine's (A4M) Nineteenth World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies, Spring and Winter Sessions (2011 conference year). Also includes Anti-Aging Clinical Protocols, 2012-2013,

Sujets

• Medical
• Médecine
• Clinical Medicine

Informations

• Publié par: eBookIt.com
• Date de parution: 21 février 2013
• Nombre de lectures: 0
• EAN13: 9781934715109
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Anti-Aging Therapeutics
Volume XIV
2011 Conference Year
 
Editors
Dr. Ronald Klatz
and
Dr. Robert Goldman
 
An official educational work published by A4M Publications
1510 West Montana Street
Chicago, IL 60614 USA
TEL: [phone]; FAX: [phone]; E-MAIL: [e-mail]
WEBSITE: www.worldhealth.net
Visit
The World Health Network, at www. worldhealth.net ,
leading Internet resource for non-commercial health information;
and
The A4M’s Special Information Center, at www.a4minfo.net , the A4M’s Publishing and Media Showcase
 


IMPORTANT – PLEASE READ
The content presented in the Anti-Aging Therapeutics, volume 14 is for educational purposes only and is specifically designed for those with a health, medical, or biotechnological education or professional experience. Anti-Aging Therapeutics, volume 14 does not prevent, diagnose, treat or cure disease or illness.
While potentially therapeutic pharmaceuticals, nutraceuticals (dietary supplementation) and interventive therapies are described in the A4M's Anti-Aging Therapeutics, volume 14 , this work serves the sole purpose of functioning as an informational resource. Under no circumstances is the reader to construe endorsement by A4M of any specific companies or products. Quite to the contrary, Caveat Emptor. It is the reader's responsibility to investigate the product, the vendor, and the product information.
Dosing of nutraceuticals can be highly variable. Proper dosing is based on parameters including sex, age, and whether the patient is well or ill (and, if ill, whether it is a chronic or acute situation). Additionally, efficiency of absorption of a particular type of product and the quality of its individual ingredients are two major considerations for choosing appropriate specific agents for an individual's medical situation.
Furthermore, anyone with malignancy should consult their physician or oncologist prior to beginning, or continuing, any hormone therapy program.
Finally, please be mindful that just because a product is natural doesn't mean it's safe for everyone. A small portion of the general population may react adversely to components in nutraceuticals (especially herbal products). A complete inventory of interventions utilized by a patient should be maintained by physicians and health practitioners dispensing anti-aging medical care.
Anti-Aging Therapeutics, volume 14 is, again, designed for those with a health, medical, or biotechnological education or professional experience. It is not intended to provide medical advice, and is not to be used as a substitute for advice from a physician or health practitioner. If you are a consumer interested in any of the approaches discussed in these chapters, it is absolutely essential that you have a thorough discussion with your physician to understand all benefits and risks.
For those individuals interested in the diagnostics and/or therapies described by chapter authors of Anti-Aging Therapeutics, volume 14 , A4M urges that you consult a knowledgeable physician or health practitioner, preferably one who has been Board Certified in Anti-Aging Medicine. You may find one by utilizing the Anti-Aging Directory at www.a4m.com.
 
 
Chapter 23 © Copyright by Pramod Vora and printed with permission of the author.
Anti-Aging Therapeutics volume 14 Copyright © 2012. American Academy of Anti-Aging Medicine.
1510 West Montana Street; Chicago IL 60614 USA.
All rights reserved.
 
Published in eBook format by A4M American Academy of Anti-Aging Medicine
Converted by http://www.eBookIt.com
 
 
ISBN-13: 978-1-9347-1510-9
 
 
Electronic and/or print reproduction, storage in an electronic and/or physical retrieval system, or transmission by any means (electronic, mechanical, photocopying, microfilming, recording, or otherwise) requires the advance written consent by the publisher.
 
 
 
* Denotes speaker at Spring 2011 Session of the Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies;
** Denotes speaker at Winter 2011 Session.
Chapter 1
Pilot Study: The Effects of Stem Cells and Platelet Rich Plasma on Recovery from Laser Resurfacing
Robert Bowen M.D., FCCP, FASLMS
Clinical Associate Professor of Medicine, WVU-East;
Medical Director, The Center for Positive Aging, Martinsburg, WV
 
ABSTRACT
This paper presents the results of a pilot study into whether stem cells or cellular growth factors would improve the efficacy of fractional laser resurfacing of the skin and/or reduce recovery time.
 
Keywords: laser resurfacing, fractional laser, adipose derived stem cells, platelet rich plasma, platelet derived growth factors, facial aging, burn scars, acne scars
 
INTRODUCTION
The development of fractional laser resurfacing has allowed effective treatments with shorter recovery than after full-field resurfacing. 1,2 This technique has been applied to the process of the aging face (wrinkles, texture irregularities, skin laxity, and sun damage), as well as treatment of surgical, acne, and burn scars. 2-4 A variety of infrared wavelengths, each with a different absorption coefficient (affinity for water) has been used successfully (1319 nm, 1320 nm, 1440 nm, 1450 nm, 2750 nm, 2940 nm, 10,600 nm). The 2940 nm Er:YAG laser and the 10,600 nm CO 2 laser have a high coefficient for absorption for water and are capable of complete ablation of tissue. These wavelengths have been effective for treating aging skin with reduced recovery times and approach but may not often achieve the results of full field resurfacing. The recent discovery of the regenerative properties of adult stem cells and platelet-derived growth factors (PDGFs) has raised questions as to whether stem cells or cellular growth factors would improve the efficacy or reduce the recovery time of these procedures.
 
PILOT STUDY
Stem Cells
Stem cells have the characteristics of both being able to replicate themselves and differentiate into a variety of other cells. 5 Embryonic stem cells (ESCs) are truly pluripotent, meaning that they can become any type of human cell. Significant scientific and ethical issues still surround the use of ESCs, thus limiting their application. Fortunately, adult mesenchymal stem cells are multipotent and are plentiful in both bone marrow and adipose tissue. 6 Adipose derived mesenchymal stem cells (ADSCs) can differentiate into vascular tissue, bone, cartilage, and adipoctyes among others. In addition to their cellular regenerative potential, these cells also exhibit chemotaxis and the ability to modulate inflammation via cytokines. 6-8
Subcutaneous fat is a rich source of ADSCs, is available in sufficient quantities and can be harvested under local anesthesia. 8 PDGFs can also be obtained by simple procedures of phlebotomy and centrifugation and also hold regenerative potential.
 
Materials and Methods
Three volunteers, skin type two and three, were tested in separate one-centimeter square areas with the ER:Yag laser (Sciton, Palo Alto, CA). Three 1 cm 2 squares were treated at 100 microns depth with a 100% coverage (full field) and three 1 cm 2 squares at 300 microns depth with 11% coverage (fractional) in each subject. Each treated area had topical application of; 1) gel vehicle only 2) gel and platelet rich plasma (PRP) 3) gel, PRP,and ADSCs. ADSCs were obtained from a “mini-liposuction” procedure using tumescent anesthesia and PRP was obtained from peripheral blood. The biologic agents were then topically applied to the wounds with a pipette and allowed to dry for 5 minutes. The treated skin was dressed with a gel to maintain the cells in an anaerobic environment. Sequential photographs were obtained and evaluated.
 
Results
Fractional wounds under all conditions healed rapidly. Epithelialization occurred within 24 hours or less in all 9 fractional wounds. 100 micron full field wounds healed more slowly. The surface area that had re-epithelialized was measured and compared to the total area of the wound and a percent healing was calculated. Mean time 50% epithelialization in the vehicle only group was 10 days, compared with 6 days in the PRP group, and 4 days in the PRP plus ADSCs group. Full re-epithelialization was achieved in a mean of 14 days with PRP and 7 days with PRP plus ADSCs. None of the areas treated with the gel vehicle alone were fully healed at the end of the 14 day observation period.
 

 
Figure 1. 5 days post-treatment: 100 micron full field resurfacing (top), 300 micron 11% fractional resurfacing (bottom), vehicle dressing only (left), vehicle + PRP (center), vehicle+ PRP+ ADSCs (right)
 

 
Figure 2. 7 days post-treatment: 100 micron full field resurfacing (top), 300 micron 11% fractional resurfacing (bottom), vehicle dressing only (left), vehicle + PRP (center), vehicle+ PRP+ ADSCs (right)

 
Figure 3. 8 days post-treatment: 100 micron full field resurfacing (top), 300 micron 11% fractional resurfacing (bottom), vehicle dressing only (left), vehicle + PRP (center), vehicle+ PRP+ ADSCs (right)
 
CONCLUDING REMARKS
This pilot study showed faster healing times compared to a vehicle dressing only of laser wounds treated with PRP and PRP plus ADSCs. These results suggest the possibility of reduced recovery times from full field laser resurfacing treatment.
The PRP and PRP plus ADSCs were applied topically using a pipette to the forearm and abdominal skin of volunteers. Facial skin heals more quickly than abdominal and forearm skin and thus healing after treatment with PRP and ADSCs is likely to be more rapid than that observed in the forearm and abdominal skin treated in this study. Administration of the PRP and cells with a pipette, as was done in this study, is not likely to be practical when treating facial skin and further work is planned using a canula or a needle to implant these biological agents in the subcutaneous space and/or dermis of subjects just prior to treatment with the laser. A